Search

Your search keyword '"Jeffrey A"' showing total 7,225 results

Search Constraints

Start Over You searched for: Author "Jeffrey A" Remove constraint Author: "Jeffrey A" Journal journal of urology Remove constraint Journal: journal of urology
7,225 results on '"Jeffrey A"'

Search Results

1. MP16-17 PHASE I STUDY OF INTRAVESICAL FC-OPTIMIZED ANTI-CD40 AGONIST ANTIBODY 2141-V11 FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)

2. MP02-18 APPROPRIATENESS OF IMAGING FOR LOW-RISK PROSTATE CANCER – REAL WORLD DATA FROM THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATION (PURC)

3. MP53-03 REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

5. MP75-10 NOCTURIA ACROSS THE HEART FAILURE CONTINUUM: RESULTS FROM AN OUTPATIENT UROLOGY POPULATION

6. PD02-06 COMPREHENSIVE GENOMIC PROFILING (CGP) OF CLINICAL T2-4N0M0 MUSCLE-INVASIVE BLADDER CANCER (MIBC) TREATED WITH NEOADJUVANT PEMBROLIZUMAB OR CISPLATIN-BASED CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY (RC)

7. PD61-09 COMPARISON BETWEEN THREE CONTEMPORARY APPROACHES OF SINGLE-PORT ROBOTIC RADICAL PROSTATECTOMY: A REPORT FROM THE SINGLE-PORT ADVANCED RESEARCH CONSORTIUM INVOLVING 1800 PATIENTS

9. MP19-07 TOWARDS A TAILORED USE OF PSA DENSITY TO DECIDE WHEN TO AVOID PROSTATE BIOPSY IN MEN WITH PIRADS 3 LESIONS ACCORDING TO THE LOCATION OF THE INDEX LESION AT MP-MRI. RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES

10. MP49-01 ADDITIVE UTILITY OF 68 GA-PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN PROSTATE CANCER DIAGNOSIS: IS THERE A CASE FOR “SEEING IS BELIEVING”?

15. PD17-12 IS THERE A ROLE FOR C-11 PET-CT IN MEN WITH BIOCHEMICAL PROGRESSION OF PROSTATE CANCER AND NEGATIVE PSMA PET-CT?

19. PD34-03 INTRAOPERATIVE TRANEXAMIC ACID IN RADICAL CYSTECTOMY: IMPACT ON BLEEDING, THROMBOEMBOLISM, AND CANCER-SPECIFIC SURVIVAL

20. MP12-16 NATIONAL TRENDS IN SAME DAY DISCHARGE FOR RADICAL PROSTATECTOMY: AN EVOLUTION IN PRACTICE PATTERNS

21. MP03-11 DOES RADIATION TIMING MATTER? ADJUVANT VS. SALVAGE RADIOTHERAPY EFFECTS ON ARTIFICIAL URINARY SPHINCTER SURVIVAL

26. MP14-15 WHICH IS THE OPTIMAL MULTIMODAL MANAGEMENT OF PN1 PATIENTS WITH PSA PERSISTENCE AFTER RADICAL PROSTATECTOMY AND EXTENDED NODAL DISSECTION? RESULTS OF A LARGE, MULTI-INSTITUTIONAL DATABASE

27. MP05-09 A NOVEL METHOD TO IDENTIFY AGGRESSIVE PROSTATE CANCER WITH DNA-METHYLATION SIGNATURES FROM PROSTATE NEEDLE BIOPSY

29. MP37-13 WHEN AND WHY DO MEN REGRET HAVING RADICAL PROSTATECTOMY?

30. MP76-11 NO CLEAR INDICATION FOR PENILE IMPLANT REMOVAL AT THE TIME OF ARTIFICIAL URINARY SPHINCTER EXPLANTATION FOR CUFF EROSION

31. PD57-09 ADJUVANT OR EARLY SALVAGE RADIOTHERAPY IN NODE POSITIVE PROSTATE CANCER PATIENTS: DEVELOPMENT OF A NOVEL RISK SCORE TO IDENTIFY THE OPTIMAL CANDIDATE FOR EARLY INTENSIFICATION APPROACHES BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES

33. PD34-10 FIRST RESULTS OF NURE-COMBO: a PHASE 2 STUDY OF NEOADJUVANT NIVOLUMAB (NIVO) AND NAB-PACLITAXEL (ABX) FOLLOWED BY POSTSURGICAL ADJUVANT NIVO IN PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC)

34. PD14-04 BLADDER CANCER CTC-PDX MODEL SYSTEMS PLATFORM FOR DISCOVERING DRUGGABLE MOLECULAR PATHWAYS TO OVERCOME CISPLATIN-BASED THERAPY RESISTANCE

35. MP06-15 THE OPTILUME® DRUG COATED BALLOON FOR RECURRENT ANTERIOR URETHRAL STRICTURES: ROBUST III STUDY 4-YEAR INTERIM RESULTS

36. PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL

38. MP73-19 MULTI-INSTITUTIONAL LEARNING CURVE ANALYSIS OF THREE SINGLE-PORT ROBOTIC RADICAL PROSTATECTOMY APPROACHES FROM THE SPARC

39. MP46-06 HIGH-RISK PATIENTS UNDERGOING HoLEP HAVE FEWER INFECTIONS WITH A LONGER COURSE OF PREOPERATIVE ANTIBIOTICS: A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY

44. PD01-07 NATURAL HISTORY OF PN1 PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: COMPETING RISK ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES

46. MP47-19 EFFICACY AND SAFETY PROFILE OF TRANSDERMAL TESTOSTERONE FOR HYPOACTIVE SEXUAL DESIRE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS

50. MP41-14 HIGH DECIPHER SCORE DEFINES THE SUBGROUP MOST AT RISK OF METASTATIC PROGRESSION AMONG PATIENTS WITH LOWER GRADE TUMORS CLASSIFIED AS NCCN HIGH-RISK BASED ON ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVEL ALONE

Catalog

Books, media, physical & digital resources